References
- DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol. 2009;27(35):5861–7. doi:10.1200/JCO.2009.24.5985.
- Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals 2013;6(12):1475–506. doi:10.3390/ph6121475.
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol [Internet]. Elsevier Ltd 2009;10(5):459–66. Available from. doi:10.1016/S1470-2045(09)70025-7.
- Chinnasamy N, Rafferty Ja, Hickson I, Ashby J, Tinwell H, Margison GP, et al. O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 1997;89(5):1566–73.
- Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, et al. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma cells. Tumour Biol. 2013;34(3):1935–47.
- Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux aM, Poisson M, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 1996;74(6):839–45. doi:10.1038/bjc.1996.446.
- Kalia VK, Prabhakara S, Narayanan V. Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy. J Cancer Res Ther. 2009;(5 Suppl 1):S57–60. doi:10.4103/0973-1482.55145.
- Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol [Internet] 1985 May [cited 2015 Aug 1];11(5):943–50. Available from: http://www.sciencedirect.com/science/article/pii/0360301 685901178. doi:10.1016/0360-3016(85)90117-8.
- Dwarkanath BS, Jain VK. Energy linked modifications of the radiation response in a human cerebral glioma cell line. Int J Radiat Oncol, Biol, Phys. 1989:1033–40. doi:10.1016/0360-3016(89)90152-1.
- Kalia VK, Devi NK. Differential modification of radiation damage in 5-bromo-2-deoxy-uridine sensitized human glioma cells and PHA-stimulated peripheral leukocytes by [Internet]. Indian J Exp Biol. 1994;32(9):637–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7814043#.
- Kalia VK, Jain VK, Otto FJ. Optimization of cancer therapy. V. effects of 2-deoxy-D-glucose on radiation induced chromosomal damage in PHA-stimulated peripheral human leukocytes. Indian J Exp Biol. 1982: 884–8.
- Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BaR, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys. 1996;35(1):103–11. doi:10.1016/S0360-3016(96)85017-6.
- Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, Jalali R, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther. 2009;(5 Suppl 1):S21–6. doi:10.4103/0973-1482.55136.
- Fael Al-Mayhani TM, Ball SLR, Zhao JW, Fawcett J, Ichimura K, Collins PV, et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods 2009;176(2):192–9. doi:10.1016/j.jneumeth.2008.07.022.
- Stoczynska-Fidelus E, Piaskowski S, Bienkowski M, Banaszczyk M, Hulas-Bigoszewska K, Winiecka-Klimek M, et al. The failure in the stabilization of glioblastoma-derived cell lines: spontaneous in vitro senescence as the main culprit. PLoS One 2014;9(1):e87136. doi:10.1371/journal.pone.0087136.
- Durmaz R. Morphology of cultured cells of glioblastoma multiforme. J Neurol Sci [Turkish] 2007;24(2) # 11(2):121–8.
- Budman D, Calvert AH, Rowinsky EK. Handbook of anticancer drug development [Internet]. Pine J, editor. Lippincott Williams & Wilkins; 2003.
- Prabhakara S, Kalia VK. Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine. Indian J Med Res. 2008;128(2):140–8.
- Dhodapkar M, Rubin J, Reid JM, Burch Pa, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res. 1997;3(7):1093–100.
- Newlands ES, Blackledge GR, Slack Ja, Rustin GJ, Smith DB, Stuart NS, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65(2):287–91. doi:10.1038/bjc.1992.57.